Product Information

CAS No.	131179-95-8
Product Name	Efaproxiral

Biological Targets

HBA1·HBA2·HBB

Associated Conditions

lung cancer·neoplasm·Central Nervous System Neoplasm·breast cancer

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

Pharmacological correction of hypothermic P(50) shift does not alter outcome from focal cerebral ischemia in rats.

American journal of physiology. Heart and circulatory physiology • Vol. 282, Issue 5 • 2002

PMID: 11959653 DOI: 10.1152/ajpheart.00863.2001

Increasing P(50) does not improve DO(2CRIT) or systemic VO(2) in severe anemia.

American journal of physiology. Heart and circulatory physiology • Vol. 283, Issue 1 • 2002

PMID: 12063279 DOI: 10.1152/ajpheart.01066.2001

Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Vol. 20, Issue 14 • 2002

PMID: 12118029 DOI: 10.1200/JCO.2002.01.096

[Blood doping and cardiovascular consequences].

Presse medicale (Paris, France : 1983) • Vol. 31, Issue 40 • 2002

PMID: 12579085

Efaproxiral

CAS No.	131179-95-8
MDL No.	N/A
MF	C₂₀H₂₃NO₄
MW	341.40
InChI Key	BNFRJXLZYUTIII-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	131179-95-8
Product Name	Efaproxiral

Biological Targets

HBA1·HBA2·HBB

Associated Conditions

lung cancer·neoplasm·Central Nervous System Neoplasm·breast cancer

* The information provided here is compiled from public sources and is for reference only.

Efaproxiral

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Efaproxiral

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

Efaproxiral

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Pharmacological correction of hypothermic P(50) shift does not alter outcome from focal cerebral ischemia in rats.

Increasing P(50) does not improve DO(2CRIT) or systemic VO(2) in severe anemia.

Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.

[Blood doping and cardiovascular consequences].

Efaproxiral

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Pharmacological correction of hypothermic P(50) shift does not alter outcome from focal cerebral ischemia in rats.

Increasing P(50) does not improve DO(2CRIT) or systemic VO(2) in severe anemia.

Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.

[Blood doping and cardiovascular consequences].

Documentation